Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.: history, ownership, mission, how it works & makes money

Born in Danyang in 1998, Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ) has grown from a respiratory-device maker into a global medical-equipment group that by 2010 had exported over 620,000 oxygen concentrators and by 2020 saw 5.75 million online sales while supplying over 70% of China's AAA-grade hospital market; today the publicly listed company-with major shareholder Jiangsu Yuyue Technology Development Co., Ltd. holding 26.53%, founder-chairman Wu Guangming at 10.32%, Wu Qun at 7.72%, and about 998.20 million shares outstanding-reported 2024 revenue of 7.57 billion RMB (down 5.09% year-on-year) and earnings of 1.81 billion RMB (down 24.63%), a market capitalization of 35.70 billion RMB as of December 12, 2025, and declared a 0.40 RMB per-share dividend (yield 1.12%); guided by a mission to "alleviate patients' suffering and enhance doctors' medical capabilities," Yuyue allocates about 10% of annual revenue to R&D, operates R&D and manufacturing centers across Germany and multiple Chinese cities, sells respiratory, diagnostic, rehabilitation and other devices in over 20 countries (international sales ≈25% of revenue in 2022), and leverages diversified product lines, service contracts and institutional partnerships to underpin a projected ~15% revenue growth target while holding an estimated 10% domestic market share in China

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ): Intro

• Founded in 1998 in Danyang, Jiangsu province as a medical device manufacturer focused on respiratory care devices and diagnostic tools.
• 2005: Sphygmomanometer awarded recognition as a 'China Brand,' an early national honor in the Chinese medical equipment sector.
• By 2010: Exported over 620,000 oxygen concentrators and became the world's top seller for 11 consecutive years (global leadership in oxygen therapy devices).
• 2018: Reported annual revenue of 4.183 billion RMB and net income of 727 million RMB, reflecting rapid scale-up of manufacturing and distribution.
• 2020: Online sales reached 5.75 million units (ranked first for 10 consecutive years); products covered over 70% of China's AAA-grade hospital market share.
• 2024: Revenue of 7.57 billion RMB (down 5.09% vs. prior year 7.97 billion RMB); earnings of 1.81 billion RMB (down 24.63%).

• Publicly listed on Shenzhen Stock Exchange: ticker 002223.SZ.
• Shareholder mix: institutional investors, strategic corporate investors, and retail shareholders typical for a large Chinese medical-device listed company.
• Subsidiaries and manufacturing bases concentrated in Jiangsu province with export-oriented production lines for respiratory devices (oxygen concentrators, nebulizers), consumables, and diagnostic instruments.

• Mission: Develop accessible, reliable medical devices to improve global respiratory and diagnostic care.
• Vision: Maintain leadership in respiratory device market share and expand into adjacent medical equipment categories and services.
• Core values: quality, affordability, innovation, and wide hospital network penetration.

• Product lines: oxygen concentrators, nebulizers, sphygmomanometers, pulse oximeters, diagnostic tools, and disposable consumables.
• Sales channels: hospital tenders (AAA-grade hospitals dominant), retail pharmacies, e-commerce (notably large online unit volumes), and international distributors/exports.
• Manufacturing: in-house mass production for cost control and scale; R&D centers for product iteration and regulatory approvals (domestic and export markets).
• After-sales: warranties, maintenance services, and consumables replacement programs to drive recurring revenue.

• Leadership in oxygen concentrator global sales historically and dominant share in domestic AAA hospital procurement.
• Strong e-commerce performance and direct-to-consumer volume (millions of units annually).
• Recognized product brands (e.g., sphygmomanometer 'China Brand') supporting tender wins and channel trust.
• Vertical integration (manufacturing + after-sales) enabling margin control and recurring revenue streams.

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ): History

• Public listing: Shenzhen Stock Exchange, ticker 002223.SZ.
• Core product lines: respiratory care, infection control, disposable medical supplies, home healthcare devices.
• Growth drivers: domestic healthcare demand, aging population, export expansion, and pandemic-related product demand spikes.

Ownership Structure

• Major shareholder: Jiangsu Yuyue Technology Development Co., Ltd. - 26.53% stake.
• Founder & Chairman Wu Guangming - 10.32% stake.
• Key individual Wu Qun - 7.72% stake.
• Total shares outstanding: approximately 998.20 million shares (as of December 12, 2025).

How It Works & Makes Money

• Manufacturing and sales of medical devices (hospital and home care): primary revenue source.
• Disposable medical supplies and consumables: recurring-revenue segment with steady margins.
• After-sales services, maintenance contracts, and parts: incremental margin support.
• Exports and OEM partnerships: diversify revenue across domestic and international markets.

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ): Ownership Structure

• Mission and values: patient-first, clinical excellence, and innovation-driven product development.
• Strategic focus areas: clinical medical devices, rehabilitation solutions, emergency care, and ophthalmology.
• Global commitment: deliver high-quality, innovative products and services to patients and healthcare institutions worldwide.

• R&D intensity: invests approximately 10% of annual revenue into research and development to sustain technological leadership.
• Research & manufacturing centers: Germany, Shanghai, Nanjing, Suzhou, Danyang, Xizang, Shenzhen, and additional domestic & international sites.
• Recognition: awarded titles such as 'Pioneer in Corporate Social Responsibility' and listed among 'China's Top 100 Listed Companies in ESG Best Practices.'

• Institutional investors (domestic & international funds): ~45% of free-float exposure through mutual funds, insurers, and ETFs.
• Retail investors: ~35%, reflecting active retail trading on the Shenzhen exchange.
• Insiders and strategic shareholders (founders, management, partnership entities): ~20%, providing operational continuity and strategic direction.

• Product sales: majority from medical devices (hospital equipment, oxygen therapy, respiratory devices) and rehabilitation equipment sold to hospitals, clinics, distributors, and end consumers.
• Service and after-sales: maintenance, consumables, and extended warranty services increase recurring revenue and customer retention.
• New growth streams: higher-margin emergency-care and ophthalmology product lines, plus international OEM/ODM contracts.

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ): Mission and Values

• R&D and innovation: multidisciplinary teams focusing on respiratory care, diabetes management, diagnostics, emergency care and rehabilitation.
• Manufacturing footprint: multiple production centers to scale manufacturing and maintain supply continuity.
• Sales & distribution: a mix of direct sales, dealer networks and institutional contracts across domestic and international channels.
• After-sales & service: technical support, warranty services and reagent/device consumable supply to secure recurring revenue.

• Respiratory solutions: oxygen concentrators, nebulizers, ventilators and accessories.
• Diabetes management: blood glucose meters, test strips and lancets.
• Medical diagnostics: point-of-care analyzers and monitoring devices.
• Rehabilitation & mobility: wheelchairs, patient lifts and related aids.
• Emergency care: automated external defibrillators (AEDs) and first-aid devices.
• Traditional Chinese medicine solutions: devices and disposables supporting TCM therapies.

• Product sales: one-time sales of devices (oxygen concentrators, AEDs, wheelchairs, etc.) constitute the majority of revenue.
• Consumables & disposables: recurring sales from strips, reagents, filters and accessories provide steady, higher-margin income.
• Service & maintenance: warranty extensions, maintenance contracts and technical services for institutional clients.
• OEM/ODM contracts: manufacturing and design-for-hire for international partners and local healthcare companies.
• Export sales: international distributors and tender wins for public health procurement.

• Expand global market share through strengthened distribution and localized partnerships.
• Increase recurring revenue from consumables, reagents and service contracts.
• Enhance R&D cooperation between Germany and China to accelerate product upgrades and regulatory clearances.
• Optimize manufacturing footprint to balance cost, lead times and supply resilience.

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ): How It Works

• Manufacturing & Product Sales: Core revenue from production and sale of respiratory care devices (oxygen concentrators, nebulizers, ventilators), blood pressure monitors, surgical disposables and diagnostic instruments.
• Healthcare Services & Solutions: Maintenance, calibration, extended warranties, equipment leasing and managed service contracts for hospitals, clinics and community health centers.
• Distribution & Channel Partnerships: Sales through domestic distributors, e‑commerce platforms and direct institutional contracts with healthcare providers.
• Export Sales: International distribution to Europe, Asia, Africa and Latin America; export sales accounted for approximately 25% of total revenue in 2022.
• R&D and Collaborative Projects: Joint development, licensing and co‑development agreements with hospitals, universities and research institutes to expand product portfolio and meet regulatory requirements.

• Product mix - higher-margin respiratory and monitoring devices versus lower-margin disposables.
• After-sales services and consumables - recurring revenue from maintenance, parts and consumables.
• Geographic diversification - domestic market scale balanced by export growth and localized channel partners.
• Partnerships - collaborations with healthcare institutions and universities to accelerate clinical validation and market acceptance.

• Manufacturing footprint and quality certifications enabling scale and regulatory approvals for export.
• Service network and technical teams delivering installation, preventive maintenance and rapid-response repairs.
• Channel strategy combining institutional sales, distributors and digital platforms to reach retail and professional buyers.
• Strategic alliances with hospitals and universities that drive clinical trials, product improvement and procurement contracts.

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ): How It Makes Money

• Domestic market share: ~10% (China medical device market)
• International sales: ~25% of total revenue in 2022
• Forecast revenue growth: ~15% for the upcoming fiscal year
• Key growth regions: Southeast Asia and Europe

• Sales of respiratory and emergency care devices to hospitals and clinics
• Consumables and disposables sold through national distribution partners
• EXPORT sales to dealers and healthcare providers in Southeast Asia, Europe and other overseas markets
• After-sales services, maintenance contracts, and value-added service packages

• Robust supply chain and manufacturing scale enabling competitive cost structure
• Extensive distribution network across tier-1 to tier-4 Chinese cities
• R&D-led product innovation and collaborations with healthcare institutions and universities
• Strategic partnerships for market access and clinical validation

• Ongoing collaborations with hospitals and universities to co-develop clinical-grade products and accelerate market adoption
• Expansion of international sales channels and localized support to boost overseas revenue share
• Investment in R&D to broaden high-margin product portfolio and maintain competitiveness